Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04106193
Other study ID # SDR 18-150
Secondary ID Iverson Miller S
Status Completed
Phase N/A
First received
Last updated
Start date November 1, 2020
Est. completion date September 30, 2023

Study information

Verified date October 2023
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Up to 20% of women Veterans (WV) using VHA primary care experience past-year intimate partner violence (IPV), which contributes to numerous physical and mental health conditions, including suicidality. Despite national recommendations to screen WVs for IPV, there is low adoption of IPV screening programs in primary care. In response, VHA is spreading IPV screening programs in Women's Health Model 1 and Model 2 primary care clinics, where the majority of WV VHA primary care patients receive care. The systematic and effective implementation of IPV screening programs within primary care clinics is expected to enhance care for WVs as well as improve access to, and timeliness of, IPV-related care. Given the high prevalence of IPV among WVs and its significant negative health effects, successful implementation of IPV screening programs is expected to reduce morbidity among WV VHA patients. This stepped wedge hybrid II implementation/effectiveness study will assess efforts to implement routine IPV screening for WV VHA patients.


Description:

Background: Intimate partner violence (IPV) is common among women Veterans (WVs), with nearly 20% of WVs treated in Veterans Health Administration (VHA) primary care clinics experiencing past-year IPV. VHA's Women's Health Services (WHS), the IPV Assistance Program, and the Offices of Primary Care and Mental Health and Suicide Prevention developed recommendations for implementing IPV screening programs in primary care. More than two-thirds of WV primary care patients receive care in "Model 1" (i.e., mixed-gender primary care) and "Model 2" (i.e., separate but shared space) clinics, but uptake of screening is low in these clinics. WHS therefore plans to use Blended Facilitation (BF) to roll out IPV screening programs in Model 1 and Model 2 primary care clinics. Given the high number of these clinics throughout VHA, it is unclear whether resource-intensive BF is feasible and whether a less intensive strategy (i.e., toolkit + Implementation as Usual [IAU]) can be effective. Research is also needed on the clinical effectiveness of IPV screening programs. Significance/Impact: Given the high prevalence of IPV among WVs and its significant health effects, successful implementation of IPV screening programs is expected to improve healthcare services and reduce morbidity among WV VHA patients, an HSR&D priority area. Innovation: This study will be the most comprehensive evaluation of both the implementation impact and clinical effectiveness of IPV screening programs globally. It is innovative in its inclusion of four strong VHA operations partners dedicated to successful implementation of IPV screening programs. This project capitalizes on a time-sensitive opportunity to advance IPV screening programs and implementation science. Specific Aims: This objective of this proposal is to comprehensively evaluate two strategies for implementing IPV screening programs through achieving three specific aims. 1. Evaluate the degree of reach, adoption, implementation fidelity, and maintenance achieved using two implementation strategies for IPV screening programs. 2. Evaluate the clinical effectiveness of IPV screening programs, as evidenced by disclosure rates and post-screening psychosocial service use. 3. Identify multi-level barriers to and facilitators of IPV screening program implementation and sustainment. Methodology: The investigators propose a cluster randomized, stepped wedge, Hybrid Type II program evaluation design to compare the impact of two implementation strategies (BF + toolkit vs. toolkit + IAU) and the clinical effectiveness of IPV screening programs. This study will use a mixed methods approach to collect quantitative (clinical records data) and qualitative (key informant interviews) implementation outcomes (Aims 1 and 3), as well as quantitative (clinical records data) clinical effectiveness outcomes (Aim 2). The investigators will supplement these data collection methods with surveys to assess implementation strategies survey to be completed pre-BF, post-BF, and in the maintenance phase. The integrated-Promoting Action on Research Implementation in Health Services (i-PARIHS) framework will guide the qualitative data collection and analysis. Summative data will be analyzed using the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) Framework. Next Steps/Implementation: This study's four VHA operations partners are eager to use the study results to inform future implementation strategies and clinical practices to spread IPV screening programs to all VHA primary care clinics and other clinical settings so that this vital intervention is accessible to all WV VHA patients.


Recruitment information / eligibility

Status Completed
Enrollment 7421
Est. completion date September 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Women Veterans age 18+ - Presenting for care at participating VA-based primary care clinics. - Due to be screened for intimate partner violence (IPV) Exclusion Criteria: - IPV screen completed in past year.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Blended Facilitation
Blended facilitation consists of an External Facilitator and Internal Facilitator to support adoption of intimate partner violence screening practices for WVs treated in primary care.
Implementation as usual
Implementation as usual refers to traditional, site-initiated support for screening practices to detect intimate partner violence among WVs treated in primary care.
Toolkit
All study arms will feature a toolkit meant to guide sites' adoption of intimate partner violence screening among WVs treated in primary care.

Locations

Country Name City State
United States VA Gulf Coast Veterans Health Care System, Biloxi, MS Biloxi Mississippi
United States VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA Boston Massachusetts
United States VA Long Beach Healthcare System, Long Beach, CA Long Beach California
United States Orlando VA Medical Center, Orlando, FL Orlando Florida
United States Hunter Holmes McGuire VA Medical Center, Richmond, VA Richmond Virginia
United States VA Northern California Health Care System, Mather, CA Sacramento California
United States VA San Diego Healthcare System, San Diego, CA San Diego California
United States Southern Arizona VA Health Care System, Tucson, AZ Tucson Arizona
United States Jonathan M. Wainwright Memorial VA Medical Center, Walla Walla, WA Walla Walla Washington
United States VA Greater Los Angeles Healthcare System, West Los Angeles, CA West Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
VA Office of Research and Development VA Boston Healthcare System

Country where clinical trial is conducted

United States, 

References & Publications (2)

Iverson KM, Dichter ME, Stolzmann K, Adjognon OL, Lew RA, Bruce LE, Gerber MR, Portnoy GA, Miller CJ. Assessing the Veterans Health Administration's response to intimate partner violence among women: protocol for a randomized hybrid type 2 implementation- — View Citation

Ogden SN, Dichter ME, Bazzi AR. Intimate partner violence as a predictor of substance use outcomes among women: A systematic review. Addict Behav. 2022 Apr;127:107214. doi: 10.1016/j.addbeh.2021.107214. Epub 2021 Dec 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Reach (primary implementation outcome) Change in proportion of WVs seen in Model 1 and 2 clinics during the last three months of each study phase who receive IPV screening For each site, the proportion calculated at baseline (months 1-3) will be compared to the proportion calculated for the latter half of the facilitation period (months 7-9).
Primary Change in Disclosure Rate (primary clinical effectiveness outcome) Change in proportion of eligible WVs who screen positive for IPV For each site, the proportion calculated at baseline (months 1-3) will be compared to the proportion calculated for the latter half of the facilitation period (months 7-9).
Secondary Change in Psychosocial Service Use (secondary clinical effectiveness outcome) Change in proportion of WVs accepting psychosocial service referrals following a positive IPV screen who use such services within two months For each site, the proportion calculated at baseline (months 1-3) will be compared to the proportion calculated for the latter half of the facilitation period (months 7-9).
Secondary Adoption of Screening (secondary implementation outcome) Change in proportion of PC clinics completing IPV screening with eligible WVs during evaluation periods For each site, the proportion calculated at baseline (months 1-3) will be compared to the proportion calculated for the latter half of the facilitation period (months 7-9).
Secondary Change in Adoption of Referrals / Resource Provision (secondary implementation outcome) Change in proportion of PC clinics delivering IPV screening program to eligible WVs during evaluation periods, including evidence of resource provision and referral offered for those with positive screens For each site, the proportion calculated at baseline (months 1-3) will be compared to the proportion calculated for the latter half of the facilitation period (months 7-9).
Secondary Change in Implementation Fidelity (secondary implementation outcome) Change in proportion of clinics for whom WVs accept referrals attend psychosocial services within two months of positive screen For each site, the proportion calculated at baseline (months 1-3) will be compared to the proportion calculated for the latter half of the facilitation period (months 7-9).
Secondary Maintenance (secondary implementation outcome) Change in proportion of WVs seen in Model 1 and 2 clinics during the last three months of the facilitation and maintenance phases who receive IPV screening For each site, the proportion calculated in the latter half of the facilitation phase (months 7-9) will be compared to the proportion calculated for the last three months of the maintenance phase (months 19-21)
See also
  Status Clinical Trial Phase
Recruiting NCT06059196 - Adapting, Expanding and Evaluating ARCHES in Kenya N/A
Active, not recruiting NCT03573778 - IHEAL Trial: Effectiveness of a Health Promotion Intervention for Women Who Have Experienced Intimate Partner Violence N/A
Completed NCT00983593 - A Randomized Clinical Study of a Mind-Body Approach to Domestic Violence Offender Treatment N/A
Not yet recruiting NCT06178016 - Efficacy of Bystander Intervention Program in Nursing Students N/A
Recruiting NCT05564000 - Effects of Dating Violence Education Program on Bystanders' Help-giving Intention and Behavior Among College Students N/A
Completed NCT05598697 - Economic Evaluation of the MEWE Intervention N/A
Not yet recruiting NCT06252909 - Treating Common Mental Disorders in Women in Mozambique by Addressing Intimate Partner Violence in Couples N/A
Completed NCT04165291 - Comparing a Fatherhood Focused Individual Intervention to Batterer Intervention to Reduce IPV and Child Maltreatment N/A
Completed NCT04517994 - Implementation of Strength at Home for Military Couples N/A
Completed NCT04978064 - E-health Psychological Intervention in Pregnant Women Exposed to Intimate Partner Violence (eIPV) N/A
Completed NCT03261700 - Recovering From Intimate Partner Violence Through Strengths and Empowerment (RISE) N/A
Completed NCT05261230 - Vedic Counselling for Women Victims of Domestic Abuse N/A
Completed NCT01688427 - Perinatal Nurse Home Visiting Enhanced With mHealth Technology N/A
Unknown status NCT00790959 - The SASA! Study: An Evaluation of a Community Intervention to Address Gender-based Violence and Reduce HIV/AIDS Risk in Uganda N/A
Recruiting NCT05893277 - Harmony: A Combined MI and BCT Intervention to Reduce Intimate Partner Violence and Alcohol Use in South India N/A
Completed NCT03477877 - Indashyikirwa IPV Prevention Trial in Rwanda N/A
Not yet recruiting NCT03333798 - Psychosocial Intervention With Community Worker Support for Survivors of Intimate Partner Violence N/A
Completed NCT00527241 - Efficacy Trial of Raices Nuevas Phase 2/Phase 3
Completed NCT05783336 - Stepping Stones and Creating Futures Plus Pilot N/A
Completed NCT02979262 - Intimate Partner Violence and Fatherhood Intervention in Residential Substance Abuse Treatment N/A